A 68-year-old man with chronic obstructive pulmonary disease (COPD) and benign prostatic hyperplasia (BPH) presents to the outpatient clinic with complaints of persistent nasal congestion and rhinorrhea for 3 weeks. His blood pressure is 148/92 mmHg and heart rate 88/min. He has been self-medicating with over-the-counter nasal decongestant spray containing phenylephrine for 10 days. On examination, the nasal mucosa appears pale and atrophic. The patient reports no relief and worsening congestion. What is the most likely explanation for the treatment failure, and which mechanism is responsible?

Explanation

## Rhinitis Medicamentosa: Pathophysiology Chronic use of topical nasal decongestants (α1 agonists) paradoxically causes worsening nasal congestion — a phenomenon called **rhinitis medicamentosa** or rebound congestion. ## Mechanism of Rebound Congestion ### Phase 1: Initial Response (Days 1–3) - α1-mediated vasoconstriction reduces mucosal edema and nasal resistance - Nasal airway patent, patient experiences relief ### Phase 2: Compensatory Vasodilation (Days 4–10) 1. **Tachyphylaxis** to α1 agonist develops via: - Receptor desensitization (G-protein uncoupling) - Downregulation of α1 receptors - Depletion of presynaptic noradrenaline stores 2. **Rebound vasodilation** occurs as: - Endogenous vasodilators (histamine, bradykinin, prostaglandins) accumulate - Vascular permeability increases → mucosal edema worsens - Nasal resistance increases paradoxically despite continued drug use 3. **Vicious cycle** establishes: - Patient uses more decongestant to relieve congestion - Tolerance increases further - Congestion worsens ## Clinical Features of Rhinitis Medicamentosa **Key Point:** Rhinitis medicamentosa develops after **3–7 days** of continuous topical nasal decongestant use and can persist for weeks after drug discontinuation [cite:Harrison 21e Ch 373]. | Feature | Finding | |---------|----------| | **Timeline** | Develops after 3–7 days of continuous use | | **Nasal appearance** | Pale, atrophic, edematous mucosa | | **Symptoms** | Severe congestion refractory to further doses | | **Rebound duration** | 1–4 weeks after drug discontinuation | | **Risk factors** | Prolonged use (>5–7 days), frequent dosing | ## High-Yield: Tachyphylaxis vs. Rhinitis Medicamentosa **Mnemonic: TACH-Y** (Tachyphylaxis = Acute Cellular Hypersensitivity) - **Tachyphylaxis** = rapid loss of drug effect at the receptor level (hours to days), reversible upon drug washout - **Rhinitis medicamentosa** = rebound vasodilation + mucosal edema due to compensatory inflammatory mediator release (days to weeks), persistent after drug discontinuation **Warning:** The correct answer is NOT simple tachyphylaxis (option A). While tachyphylaxis does occur, the clinical phenomenon of worsening congestion despite continued drug use is primarily due to **rebound vasodilation and increased vascular permeability** — true rhinitis medicamentosa. ## Management 1. **Immediate:** Abrupt discontinuation of topical decongestant 2. **Symptomatic relief:** Intranasal corticosteroids (fluticasone, mometasone) to reduce inflammation 3. **Supportive:** Saline irrigation, humidification 4. **Systemic:** Oral antihistamines or decongestants (pseudoephedrine) as bridge therapy 5. **Prevention:** Limit topical decongestant use to ≤3–5 days ## Clinical Pearl **High-Yield:** Intranasal corticosteroids do NOT cause rhinitis medicamentosa and are safe for long-term use. They are the preferred agent for chronic rhinitis and allergic rhinitis [cite:KD Tripathi 8e Ch 12].